Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cell therapies, has announced its upcoming presentation at the Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 3, 2025, at 3:10 p.m. ET.
Steve Harr, the company's President and CEO, will provide a business overview and update during the presentation. Interested parties can access the webcast through Sana's Investor Relations webpage at https://sana.com/. The presentation recording will remain available for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA), un'azienda specializzata in terapie cellulari ingegnerizzate, ha annunciato la sua prossima presentazione al 45° Congresso Annuale sulla Salute di Cowen. La presentazione è programmata per il 3 marzo 2025, alle 15:10 ET.
Steve Harr, Presidente e CEO dell'azienda, fornirà una panoramica aziendale e un aggiornamento durante la presentazione. Le parti interessate possono accedere alla diretta streaming tramite la pagina delle Relazioni con gli Investitori di Sana all'indirizzo https://sana.com/. La registrazione della presentazione rimarrà disponibile per 30 giorni dopo la conferenza.
Sana Biotechnology (NASDAQ: SANA), una empresa especializada en terapias celulares diseñadas, ha anunciado su próxima presentación en la 45ª Conferencia Anual de Salud de Cowen. La presentación está programada para el 3 de marzo de 2025, a las 3:10 p.m. ET.
Steve Harr, Presidente y CEO de la empresa, proporcionará una visión general del negocio y una actualización durante la presentación. Las partes interesadas pueden acceder a la transmisión en vivo a través de la página de Relaciones con Inversores de Sana en https://sana.com/. La grabación de la presentación estará disponible durante 30 días después de la conferencia.
Sana Biotechnology (NASDAQ: SANA), 엔지니어링 세포 치료를 전문으로 하는 회사가 코웬 제45회 연례 건강 관리 회의에서의 발표를 발표했습니다. 발표는 2025년 3월 3일 오후 3시 10분 ET로 예정되어 있습니다.
회사의 회장 겸 CEO인 Steve Harr가 발표 중에 사업 개요 및 업데이트를 제공합니다. 관심 있는 분들은 Sana의 투자자 관계 웹페이지 https://sana.com/를 통해 웹캐스트에 접근할 수 있습니다. 발표 녹화는 회의 후 30일 동안 제공됩니다.
Sana Biotechnology (NASDAQ: SANA), une entreprise spécialisée dans les thérapies cellulaires ingénieries, a annoncé sa prochaine présentation lors de la 45ème Conférence Annuelle sur la Santé de Cowen. La présentation est prévue pour le 3 mars 2025 à 15h10 ET.
Steve Harr, le Président et CEO de l'entreprise, fournira un aperçu de l'entreprise et une mise à jour lors de la présentation. Les parties intéressées peuvent accéder au webinaire via la page des Relations Investisseurs de Sana à l'adresse https://sana.com/. L'enregistrement de la présentation sera disponible pendant 30 jours après la conférence.
Sana Biotechnology (NASDAQ: SANA), ein Unternehmen, das sich auf entwickelte Zelltherapien spezialisiert hat, hat seine bevorstehende Präsentation auf der 45. jährlichen Gesundheitskonferenz von Cowen angekündigt. Die Präsentation ist für den 3. März 2025 um 15:10 Uhr ET geplant.
Steve Harr, Präsident und CEO des Unternehmens, wird während der Präsentation einen Überblick über das Geschäft und ein Update geben. Interessierte Parteien können über die Investor Relations-Webseite von Sana unter https://sana.com/ auf das Webcast zugreifen. Die Aufzeichnung der Präsentation bleibt 30 Tage nach der Konferenz verfügbar.
- None.
- None.
SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 45th Annual Health Care Conference at 3:10 p.m. ET on Monday, March 3, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
The webcast will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, and Bothell, WA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the Cowen 45th Annual Health Care Conference; and the subject matter of the Company’s presentation at the conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-Q dated November 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
When is Sana Biotechnology (SANA) presenting at the Cowen Health Care Conference 2025?
How can investors watch Sana Biotechnology's Cowen Conference presentation?
How long will Sana Biotechnology's Cowen Conference presentation replay be available?
What will be covered in Sana Biotechnology's March 2025 Cowen Conference presentation?
